Zealand Pharma A/S (OTCMKTS:ZLDPF) Issues Earnings Results, Beats Expectations By $0.53 EPS

Zealand Pharma A/S (OTCMKTS:ZLDPF) announced its quarterly earnings results on Thursday. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.34) by $0.53, Zacks reports. Zealand Pharma A/S had a return on equity of 55.76% and a net margin of 71.79%.

Zealand Pharma A/S Price Performance

Shares of ZLDPF traded down $1.68 during trading hours on Thursday, hitting $60.42. 2,161 shares of the company were exchanged, compared to its average volume of 2,688. The company has a quick ratio of 14.10, a current ratio of 14.10 and a debt-to-equity ratio of 0.02. Zealand Pharma A/S has a fifty-two week low of $49.98 and a fifty-two week high of $101.29. The company has a market cap of $4.29 billion, a price-to-earnings ratio of 4.35 and a beta of 0.72. The firm’s fifty day moving average is $69.05 and its 200 day moving average is $70.46.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on ZLDPF. BTIG Research upgraded Zealand Pharma A/S to a “strong-buy” rating in a research note on Friday, November 28th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Zealand Pharma A/S in a research report on Tuesday, December 16th. Five analysts have rated the stock with a Strong Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy”.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.